Investors, advisory boards and stock exchange authorities frequently require professional assessment of new technologies to determine their true value proposition. This assessment may encompass an analysis of its disruptive potential, validation of its clinical utility, or characterization of its benefits and limitations relative to competitive technologies. HRI has experience conducting technology assessments of devices as well as drug-device combination products. We use a combination of in-house staff and outside consultants to ensure a comprehensive, accurate and clearly characterized assessment.
Please contact Suzanne Ratzloff
at 216-521-3321 if you would like discuss our technology assessment services.